StephN
12-21-2010, 02:55 PM
Mayo Clinic
Cancer
TapImmune Inc. has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer). Keith Knutson, M.D. will serve as Principal Investigator.
Her2/neu receptor related cancer is a very aggressive form of breast cancer that affects a subset of breast cancer patients. It is a well established therapeutic target, which helps our development goals from a regulatory standpoint. For example, Herceptin (a Her2/neu inhibitor by Genentech) is an approved drug with annual sales in excess of $4 Billion. </STRONG>
There are ongoing vaccine trials targeting Her2/neu. The major disadvantage (as we understand) of technologies that are currently in development are their inability to cover all or a majority of Her2/neu cancer patients and their ability for long-term protection. Some of them seem to be effective only in a subset of Her2/neu cancer patients due to the nature of the peptide epitopes used. Along with Mayo we believe this technology is could cover up to 90% of the Her2/neu patients and last a very long time (if not a life time), which is an improvement that could cover an additional 30% of the population who may not be covered by the other technologies that are currently in development. </STRONG>
Dr Glynn Wilson, Executive Chairman of TapImmune, stated, “The option to license this technology from Mayo Clinic represents a significant opportunity to add to our cancer vaccine portfolio and clinical research programs. We believe that this technology offers a number of advantages in the development of a breast cancer vaccine for a broad patient population
Cancer
TapImmune Inc. has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer). Keith Knutson, M.D. will serve as Principal Investigator.
Her2/neu receptor related cancer is a very aggressive form of breast cancer that affects a subset of breast cancer patients. It is a well established therapeutic target, which helps our development goals from a regulatory standpoint. For example, Herceptin (a Her2/neu inhibitor by Genentech) is an approved drug with annual sales in excess of $4 Billion. </STRONG>
There are ongoing vaccine trials targeting Her2/neu. The major disadvantage (as we understand) of technologies that are currently in development are their inability to cover all or a majority of Her2/neu cancer patients and their ability for long-term protection. Some of them seem to be effective only in a subset of Her2/neu cancer patients due to the nature of the peptide epitopes used. Along with Mayo we believe this technology is could cover up to 90% of the Her2/neu patients and last a very long time (if not a life time), which is an improvement that could cover an additional 30% of the population who may not be covered by the other technologies that are currently in development. </STRONG>
Dr Glynn Wilson, Executive Chairman of TapImmune, stated, “The option to license this technology from Mayo Clinic represents a significant opportunity to add to our cancer vaccine portfolio and clinical research programs. We believe that this technology offers a number of advantages in the development of a breast cancer vaccine for a broad patient population